Broussard, Quebec, April 16, 2024 (GLOBE NEWSWIRE) — Diagnos Inc. (“DIAGNOS” or the “Firm”) (TSX Enterprise: ADK) (OTCQB: DGNOF) is a medical firm that gives early detection of sure important illnesses. Supplier Well being Issues, at this time introduced that it’s working to acquire approval from Well being Canada and the FDA for 4 further synthetic intelligence evaluation modules for commercialization within the third quarter of 2024.
These new additions to the DIAGNOS service will present our clients with versatile AI-assisted picture processing and evaluation options for the detection of a variety of retinopathy within the normal inhabitants. Particularly, the brand new module is designed to assist healthcare professionals establish generally irregular optical coherence tomography retinal photos and grade fundus photos because it pertains to AMD (age-related macular degeneration), DR (diabetic retinopathy) or HR (hypertensive retinopathy).
“These soon-to-be-licensed AI analytics modules are being developed in a fashion in line with present and upcoming steering associated to AI medical units from regulators and legislators world wide. Synthetic intelligence has entered our lives and is poised to play a serious function in affected person care, There aren’t any limits to the appliance of synthetic intelligence in drugs, and it has nice potential to assist and assist healthcare professionals in bettering medical outcomes and total high quality of life for sufferers. André Larente, President DIAGNOS.
These new synthetic intelligence evaluation modules will present DIAGNOS with the chance to develop income quicker. Our present consumer, the Authorities of Quebec, has requested the modernization of our Well being Canada license, which is a prerequisite for Essilor Luxottica to distribute our companies in Canada and, sooner or later, the US market. DIAGNOS can also be dedicated to ISO 27001 cyber safety purposes, a certification required by our clients and potential clients.
About analysis
DIAGNOS is a Canadian public firm devoted to early detection of great well being issues based mostly on its FLAIRE synthetic intelligence (AI) platform. FLAIRE permits speedy modification and improvement of purposes comparable to CARA (Pc Assisted Retinal Evaluation). CARA’s picture enhancement algorithms present retinal photos which might be sharper, clearer and simpler to research. CARA is an economical software for point-of-care screening of enormous numbers of sufferers.
For extra data, see: www.diagnos.com and www.sedar.com
Neither the TSX Enterprise Trade nor its Regulation Companies Supplier (as that time period is outlined within the insurance policies of the TSX Enterprise Trade) accepts duty for the adequacy or accuracy of this launch.
This press launch accommodates forward-looking data. There will be no assurance that forward-looking data will show to be correct, as precise outcomes and future occasions may differ materially from these anticipated in these statements. DIAGNOS disclaims any intention or obligation to publicly replace or revise any forward-looking data, whether or not on account of new data, future occasions or in any other case. The forward-looking data contained on this press launch is expressly certified by this cautionary assertion.
CONTACT: For additional data, please contact: Mr. André Larente, President DIAGNOS Inc. Tel: 450-678-8882 ext. 224 alarente@diagnos.com
![](https://s.yimg.com/ny/api/res/1.2/Fn6ODSo.YAQbvzLddzVdCg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MA--/https://ml.globenewswire.com/media/MDMxMjgyZGEtNGY2Ni00MDA1LWEwYzQtOWEzOTY2YzdlZGNjLTExMDUzODk=/tiny/DIAGNOS-Inc-.png)